on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has revealed its position in Avadel Pharmaceuticals plc through a Form 8.3 filing. This disclosure, submitted under Rule 8.3 of the Irish Takeover Panel Act, 1997, concerns entities with interests in relevant securities representing 1% or more.
The filing details The Vanguard Group's ownership of 5,852,019 ordinary shares of Avadel Pharmaceuticals, equivalent to a 6.01% stake. Additionally, transactions include the purchase of 445 shares and the sale of 19,587 shares, both at a unit price of 21.50 USD.
No cash-settled or stock-settled derivative positions were reported, and there are no indemnity or option arrangements, agreements, or understandings related to these securities. The disclosure highlights The Vanguard Group's ongoing interests in Avadel Pharmaceuticals as part of its investment strategy.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news